Abstract Procedure

GENERAL GUIDELINES FOR ABSTRACT SUBMISSION ACSICON 2023

  • Abstract submission is open for only.
  • Abstract submission closes on 15th August 2023
  • Abstracts can be submitted under following categories – Award paper, Free paper and e-Poster
  • You may submit more than one abstract in each category. But maximum of only one free paper would be accepted per delegate for oral presentation, other submissions from same delegate will be converted to e-Poster if found suitable
  • Acceptance or rejection of paper will be conveyed by email

ABSTRACT PREPARATION GUIDELINES

Please specify any of the three categories in which you would like your abstract to be considered.

SUBMISSION CATEGORIES

  • Nail
  • Skin and Mucosa
  • Hair
  • All abstracts must be submitted in English language using the font Times New Roman, with a font size of 12 and 1.5 spacing.
  • To ensure blinded review, no identifying features such as names of authors, collaborators, hospitals, medical colleges, clinics or places should be listed in the title or text page of the abstract. Author details and their affiliation(s) should be entered online while doing the submission.
  • Title should be written using ‘Sentence case’ and should be brief and self-explanatory.
  • Avoid abbreviations in the title.
  • Word limit of the abstract is 250 words. (Excluding title, authors, their affiliations etc.)
  • Structure of the abstract for original study should be:
    • Aims and objectives
    • Materials and Methods
    • Results
    • conclusions
  • Structure of the abstract for case reports and case series should be:
    • Introduction
    • Case details (history, examination finding, investigations and treatment)
    • Discussion
  • Please refer the provided template for E- poster submission (case report/series and original study)
  • Please ensure that the abstract contains original matter neither published prior in print or electronic media or presented in previous conferences.
  • Refrain from using keywords, graphs, figures, tables or references in the abstract.
  • Conflict of interest statement and declaration of conflict is mandatory.
  • Use generic names of drugs or its active pharmacological content, avoiding commercial names of drugs/companies.
  • Limit the use of abbreviations and acronyms in the abstract.
  • Responsibility of avoiding plagiarism lies with the authors.
  • Non-adherence to any guideline may result in an automatic rejection of the abstract.
  • Once uploaded successfully, you will get a communication acknowledgement.
  • The abstract should be submitted to the submission platform only after registering for the conference. No abstract submission shall be entertained by any other means.
  • Please check the conference website from time to time for all updates.